Overview
Exploring the safety and efficacy of the therapy combining immune checkpoint inhibitors (anti-PD-L1 monoclonal antibody, ASC22) and pegylated interferon alfa (Peg-IFNα) in patients with CHB. Exploring new combination therapeutic schemes for hepatitis B cure, and raising the overall clinical cure rate to more than 50% without screening specific advantageous groups.
Eligibility
Inclusion Criteria:
- Body mass index (BMI) of 18 to 32 kg/m\^2;
- Serum HBsAg\<100 IU/mL;
- HBV DNA\<20 IU/mL;
- HBeAg-negative.
Exclusion Criteria:
- A history of allergy, or who are suspected by the researcher to be allergic to the active ingredient of the drug under study or its excipients;
- Use of immunosuppressants, immunomodulators (thymosin) and cytotoxic drugs within 6 months before enrollment, or vaccination of live attenuated vaccine within 1 month before enrollment;
- Acute infection within 2 weeks before enrollment which requires intravenous antibiotic treatment, or existing infection which requires anti-infection treatment when enrollment;
- Confirmed or suspected decompensated cirrhosis;
- Malignant tumors;
- Serious diseases of circulatory, respiratory, urinary, blood, metabolic, immune, mental, neurological, renal and other systems;
- Hepatitis C virus (HCV) antibody (+), HIV antigen/antibody (+), or treponema pallidum antibody (+) and rapid plasma regain (RPR) test (+);
- Female in suckling period or pregnancy test (+) during screening;
- Subjects who are considered by the researcher to have other factors that are not suitable for the study
